{"id":"anakinra-r-methuil-1ra","safety":{"commonSideEffects":[{"rate":"71","effect":"Injection site reactions"},{"rate":"7","effect":"Infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anakinra competitively inhibits interleukin-1 (IL-1) by binding to the IL-1 receptor type I, preventing both IL-1α and IL-1β from activating downstream inflammatory pathways. This blocks the production of pro-inflammatory mediators and reduces systemic inflammation. It is used primarily in autoinflammatory and autoimmune conditions where IL-1 plays a central pathogenic role.","oneSentence":"Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:36.887Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Autoinflammatory syndromes (e.g., cryopyrin-associated periodic syndromes)"},{"name":"Gout"}]},"trialDetails":[{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT04227769","phase":"PHASE2","title":"IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-01-13","conditions":"Diabetes Mellitus Type 2 in Obese, Inflammation, Metabolic Disease","enrollment":18},{"nctId":"NCT03578497","phase":"PHASE2","title":"Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2018-08-31","conditions":"Polycystic Ovary Syndrome","enrollment":18},{"nctId":"NCT00111410","phase":"PHASE4","title":"Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT00537667","phase":"PHASE2","title":"The SPECTRA Study","status":"TERMINATED","sponsor":"Amgen","startDate":"2001-08","conditions":"Rheumatoid Arthritis","enrollment":22},{"nctId":"NCT00037648","phase":"PHASE2","title":"Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2000-07","conditions":"Juvenile Chronic Arthritis","enrollment":86},{"nctId":"NCT00121043","phase":"PHASE4","title":"Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Anakinra (r-metHuIL-1ra)","genericName":"Anakinra (r-metHuIL-1ra)","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation. Used for Rheumatoid arthritis, Autoinflammatory syndromes (e.g., cryopyrin-associated periodic syndromes), Gout.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}